UY29326A1 - Metodo de tratamiento - Google Patents

Metodo de tratamiento

Info

Publication number
UY29326A1
UY29326A1 UY29326A UY29326A UY29326A1 UY 29326 A1 UY29326 A1 UY 29326A1 UY 29326 A UY29326 A UY 29326A UY 29326 A UY29326 A UY 29326A UY 29326 A1 UY29326 A1 UY 29326A1
Authority
UY
Uruguay
Prior art keywords
limited
similar
treatment method
personality
pheniclidine
Prior art date
Application number
UY29326A
Other languages
English (en)
Inventor
Jeffrey M Goldstein
Patricia C Davis
Scott W Grimm
Raymond F Suckow
Helen R Winter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29326A1 publication Critical patent/UY29326A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Método para tratar al menos síntoma o afección asociado con, pero sin limitarse, a trastornos relacionados con: - sustancias incluyendo pero sin limitarse a dependencia, abuso, intoxicación y abstinencia a sustancias - Alcohol, Anfetaminas (Similares), Cafeína, Cannabis, Cocaína, Halucinógenos, Inhalables - Nicotina, Opioides, Feniclidina (similares),Sedativos, Hipnóticos o Ansiolíticos. - déficit Atencional y Comportamiento Errático. - hábitos alimenticios. - personalidad incluyendo pero sin limitarse a trastorno de Personalidad Obsesivo-Compulsivo. - control de Impulsos, comprendiendo administración de cantidad eficaz de Fórmula I.
UY29326A 2005-01-07 2006-01-05 Metodo de tratamiento UY29326A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
UY29326A1 true UY29326A1 (es) 2006-08-31

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29326A UY29326A1 (es) 2005-01-07 2006-01-05 Metodo de tratamiento

Country Status (6)

Country Link
EP (1) EP1838325A1 (es)
JP (1) JP2008526839A (es)
AR (1) AR052191A1 (es)
TW (1) TW200640466A (es)
UY (1) UY29326A1 (es)
WO (1) WO2006073360A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360503A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 液体制剂
DK2307389T3 (da) 2008-06-20 2013-04-02 Astrazeneca Ab Dibenzothiazepinderivat og anvendelser deraf
US8389716B2 (en) 2009-01-30 2013-03-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US7304047B2 (en) * 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
US20060189599A1 (en) * 2002-10-18 2006-08-24 Green Alan I Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking
AU2004253334A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
US20070270403A1 (en) * 2003-12-04 2007-11-22 Broderick Patricia A Clozapine and Cocaine Effects on Dopamine and Serotonin Release in Nucleus Accumbens During Psychostimulant Behavior and Withdrawal
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
AR052191A1 (es) 2007-03-07
WO2006073360A1 (en) 2006-07-13
EP1838325A1 (en) 2007-10-03
TW200640466A (en) 2006-12-01
JP2008526839A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2698166A3 (en) Complement inhibition for improved nerve regeneration
WO2008036678A3 (en) Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2007030697A3 (en) Modulation of neurogenesis by hdac inhibition
WO2006131952A8 (en) Novel analgesic treatment with prolonged effect
WO2007022470A3 (en) Methods and compositions for treating neurological disease
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
TW200740804A (en) Glucokinase activators
WO2007005453A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MA31767B1 (fr) Composes organiques et leurs utilisations
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007134077A3 (en) 5 ht receptor mediated neurogenesis
WO2008039863A3 (en) Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
WO2008051797A3 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
BRPI0511477A (pt) compostos e composições como moduladores de ppar
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2007095586A3 (en) Neuronal pain pathway modulators
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160725